- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02251366
NVAMD Satellite Study
A Multi-Satellite Comparison of Standard-of-Care, Physician-Based Retinal Evaluation Versus Physician-Guided Diagnostic Evaluation in the Management of Neovascular Age-Related Macular Degeneration With Anti-Vascular Endothelial Growth Factor Therapy
Intravitreal delivery of anti-vascular endothelial growth factor (VEGF) drugs has revolutionized the management of neovascular age-related macular degeneration (NVAMD). However, the requirement for near monthly administration of therapy coupled with the growing number of patients needing treatment has become a universal challenge in efficient delivery of care for retina physicians. While many retina practices have both increased the size of their staffs to accommodate the growing patient population and increased efficiency with the aid of digital photography, patient encounter times in clinic continue to increase, often spanning 2-4 hours. While maintaining the highest level of patient care, a streamlined alternative in the evaluation of patients with NVAMD to determine whether intravitreal therapy with an anti-VEGF agent is indicated at a particular office visit would be desirable.
This multi-satellite, prospective, randomized pilot study will compare standard-of-care, physician- based retinal evaluation, defined as retinal examination by a physician and standard imaging with optical coherence tomography (OCT) and optional fluorescein angiography (FA), versus physician-guided diagnostic evaluation, defined as standard imaging with OCT and optional FA without retinal examination by a physician in the management of NVAMD with anti-VEGF therapy. Outcomes for this study are aimed primarily at demonstrating that the physician-guided diagnostic approach to managing patients with NVAMD is not inferior to the physician-based retinal evaluation based on measures such as a change from baseline in visual acuity and in central subfield thickness (CSF) on OCT. Other outcomes to be assessed in this study are length of visit times, numbers of intravitreal injections of anti-VEGF agents administered, numbers of diagnostic tests performed to determine whether treatment should be given at each visit, and frequency of retinal examinations performed for each participating patient in each cohort. Perceptions of quality of vision and patient satisfaction will be captured by interviews with patients following each clinic visit; clinical impressions of physicians will be captured by a brief physician survey. Finally, the feasibility of recruiting patients, as measured by how many eligible patients are seen at each Wilmer satellite, how many patients agree to be randomized, how many patients follow-up, and the attrition rates at the 4 and 8-month outcome visits will be assessed.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Maryland
-
Bel Air, Maryland, Verenigde Staten, 21014
- Wilmer Eye Institute
-
Bethesda, Maryland, Verenigde Staten, 20814
- Wilmer Eye Institute
-
Columbia, Maryland, Verenigde Staten, 21044
- Wilmer Eye Institute
-
Frederick, Maryland, Verenigde Staten, 21702
- Wilmer Eye Institute
-
Lutherville, Maryland, Verenigde Staten, 21093
- Wilmer Eye Institute
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria:
- Established diagnosis of NVAMD in one or both eyes
- Received 2 or more intravitreal injections of anti-VEGF therapy from the retinal physician during the prior 6 months
- Need for more therapy on a near monthly basis is anticipated
- Usual corrected visual acuity (UCVA) of at least one eye must be 20/200 or better
- Must be physically able to cooperate with OCT and other diagnostic imaging procedures
- Must be able to give informed consent and be able to complete telephone surveys
Exclusion criteria:
- Systemic disease that can affect the peripheral retina (e.g., diabetes mellitus, sickle cell)
- History of symptomatic posterior vitreous detachment, retinal tear, or retinal detachment
- History of retinal surgery will not be enrolled.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: SOC Examination Based Cohort
Participants in this arm will receive standard of care (SOC) retinal examinations at each study visit.
|
|
|
Actieve vergelijker: Physician-Guided Diagnostic
Participants in this arm of the study will only receive the physical standard-of-care retinal examination at the 4-month and -month office visits, unless requested by the Physician-Investigator or study participant.
At each standard study visit, the physician will use diagnostic imaging to determine if the participant will receive the anti-VEGF injection.
|
NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Change in visual acuity from baseline
Tijdsspanne: up to two years
|
up to two years
|
|
Change in OCT CSF from baseline
Tijdsspanne: up to two years
|
up to two years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
total encounter time for each arm
Tijdsspanne: up to two years
|
up to two years
|
Andere uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Number of intravitreal anti-VEGF injections administered
Tijdsspanne: up to two years
|
up to two years
|
|
number of diagnostic tests performed
Tijdsspanne: up to two years
|
up to two years
|
|
number of retinal examinations performed
Tijdsspanne: up to two years
|
up to two years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Sharon Solomon, MD, Johns Hopkins University
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NA_00088759
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .